



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

June 21, 2022: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Medical Director Update** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 – 6:50**

- **RetroDUR/ProDUR** **6:50- 7:20**
 - Data presentation: Concurrent Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors
 - Introduce: Metabolic Monitoring for Children and Adolescents on Antipsychotics

- **Clinical Update: Drug Reviews** **7:20-7:55**
(Public comment prior to Board action)
 - Biosimilar Drug Reviews**
 - None at this time.

 - Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Apretude® (cabotegravir)
 - Livtencity® (maribavir)
 - Voxzogo® (vosoritide)
 - Vuity® (pilcarpine HCL)

- **New Managed Therapeutic Drug Classes** **7:55 -7:55**
 - None at this time
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:55 - 8:30**
(Public comment prior to Board action)

- Anticonvulsants (new drug Eprontia® (topiramate solution) included)
- Ophthalmic Antibiotics
- Ophthalmic Allergic Conjunctivitis
- Ophthalmic Glaucoma Agents
- Ophthalmic Dry Eye Agents
- Ophthalmic Anti-Inflammatory
- Stimulants and Related Agents
- Sickle Cell Anemia

- **Review of Newly Developed/Revised Criteria** **8:30 - 8:30**
(Public comment prior to Board action)
 - None at this time

- **General Announcements** **8:30 – 8:30**

- **Adjourn** **8:30**